• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Semprus lands $1 million Army grant | Funding Roundup

Semprus lands $1 million Army grant | Funding Roundup

October 19, 2011 By MassDevice staff

Semprus Biosciences

Semprus BioSciences Corp. won a $1 million grant to develop orthopedic devices resistant to biofilm formation for the U.S. Army’s Telemedicine & Advanced Technology Research Center.

Biofilms are the foundation for the most bacterial complications associated with implanted medical devices, according to a Semprus press release.

"Our goal is to dramatically reduce complication rates in orthopedic devices implanted in our men and women in the Armed Forces," CTO Christopher Loose said in prepared remarks. "We expect our technology to reduce wound complications, amputation and mortality in soldiers with orthopedic injuries."

Semprus develops technology to "coat" medical devices with its Sustain technology.

Instead of being "attached to [the device’s] surface in a temporary fashion," as CEO David Lucchino told MassDevice in a podcast interview earlier this year, Sustain is grown from the material itself as a "physical extension" of the device’s material.

Click here for MassDevice’s podcast interview with Semprus BioSciences CEO David Lucchino from February 2011.

"Think of it as billions of molecular-sized oak trees, and how you grow those oak trees out of the substrate … creates the long-term performance," Lucchino said.

The scope of the work done in collaboration with the army will focus on adapting Semprus technology to orthopedic materials, including titanium.

Funding

Here’s a roundup of other dealflow and investment news:

  • EndoEvolution lands $3.3 million in Series B
    EndoEvolution LLC, an device company developing next-generation automated suturing devices for minimally invasive surgery (MIS), raised $3.3 million in a Series B round, according to a press release.
    Read more
  • Humedica raises $23 million from 11 investors
    Humedica Inc. closed a $23 million equity funding round comprised of 11 investors, according to SEC filings.
    Read more
  • SPR Therapeutics is halfway to $2 million funding goal
    SPR Therapeutics raised $1 million of a hoped-for $2 million equity funding round with 6 investors thus far, according to SEC filings.
    Read more
  • C.R. Bard extends revolving credit up to $600 million
    C.R. Bard (NYSE:BCR) extended its unsecured credit line to $600 million over a five-year period, according to SEC filings.
    Read more
  • ProUroCare renews $900,000 promissory note
    ProUroCare Medical Inc. (OTC:PUMD), a pre-revenue company, renewed a $900,000 promissory note with Crown Bank, according to SEC filings.
    Read more
  • Opko scientist lands $4.2 million NIH grant
    Opko Health Inc. (NYSE:OPK) scientist Thomas Kodadek landed $4.2 million from the National Institutes of Health to advance research in Type I diabetes, according to a press release.
    Read more
  • Chesson Labs raises $1.45 million of a hoped-for $2 million round
    Chesson Labs Inc. inched closer to its $2 million goal for its latest funding round, having raised $1.45 million from 81 investors, according to SEC filings.
    Read more

Filed Under: Funding Roundup, Implants, News Well Tagged With: C.R. Bard, Chesson Labs Inc., EndoEvolution LLC, Humedica Inc., Opko Health Inc., ProUroCare Medical Inc., Semprus BioSciences, SPR Therapeutics LLC

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy